CloneID: 806
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing mice with NR6 mouse fibroblasts transfected with the de2-7 EGFR.
Buffer Composition: PBS only.
Chimeric Use Statement: This is a reformatted mouse IgG2b Fc Silent™ antibody, based on the original mouse IgG2b format, created for improved compatibility with existing reagents, assays and techniques.
Uniprot Accession No.: P00533
Specificity Statement: This antibody is specific for the human delta2–7 epidermal growth factor receptor (de2–7 EGFR or EGFRvIII) which is a truncated version of the EGFR commonly expressed in glioma. This antibody also binds overexpressed wild-type (wt) EGFR but not native EGFR expressed in normal tissues at physiological levels. EGFR is a transmembrane mitogenic glycoprotein with a cytoplasmically facing tyrosine kinase site which is activated by binding of the epidermal growth factor in the external domain. It also binds transforming growth factor alpha (TGFa). EGFR a member of the epidermal growth factor family and is closely related to receptor tyrosine kinases. This receptor tyrosine kinase binds ligands of the EGF family and activates signaling cascades to convert extracellular cues into appropriate cellular responses. Mutations that lead to EGFR overexpression (known as upregulation) or overactivity have been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme as well as inflammatory diseases.
Application Notes (Clone): This antibody bound de2-7 EGFR (EGFRvIII) transfected U87MG glioma cells with high affinity but did not bind parental cells that express the wild type EGFR in a flow cytometric assay. This antibody can bind wild type EGFR containing the extracellular domain only in certain conditions like when the extracellular domain was immobilized on the surface of ELISA plates (PMID: 11920591). The antitumor activity of this antibody against human tumor xenografts grown in nude mice was studied. This antibody significantly inhibited the growth of U87 MG xenografts transfected with the de2–7 EGFR in a dose-dependent manner. It further also inhibited growth of new and established A431 xenografts, a cell line expressing >10^6 EGFRs/cell (PMID: 11454674). The efficacy of this antibody, on the growth of intracranial xenografted gliomas in nude mice was also studied. It was reported that treatment of U87 MG.DEGFR tumors in mice with mAb 806 caused decreases in both tumor growth and angiogenesis, as well as increased apoptosis. In vivo mAb 806 treatment resulted in reduced phosphorylation of the constitutively active DEGFR and caused down-regulated expression of the apoptotic protector, Bcl-XL (PMID: 11454673).
English
Deutsch
